Transcenta Holding Ltd.
http://www.transcenta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Transcenta Holding Ltd.
TORL Looks To Break Ground In Growing Field Of Claudin-Targeting Drugs
The company announced a series B-2 financing of $158m that it plans to use for pivotal Phase II development of TORL-1-23, which it called a first-in-class agent.
2023 Review: Chinese-Sponsored Phase III US Trials See Uptick
Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.
Astellas’ Zolbetuximab Approval Timeline Unclear After Manufacturing Issues Prompt CRL
After a US FDA site inspection raised questions about the contract manufacturer of the potential first-in-class Claudin 18.2 inhibitor that could not be answered by the original January PDUFA date, Astellas will need to refile the application, but has not committed to when that might be.
US CRL For Astellas's Zolbetuximab Over Manufacturing Issues
Astellas has received a US CRL for it's potential first-in-class drug zolbetuximab, after questions over a manufacturing line came up after an FDA site inspection and could not be answered by the original 12 January PDUFA date. The Japanese firm will refile the application after resolving the issues, but the likely revised timeline is not yet clear.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- MabSpace Biosciences Co., Ltd.
- HJB l
- Suzhou Transcenta Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice